JP2017529870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529870A5 JP2017529870A5 JP2017525496A JP2017525496A JP2017529870A5 JP 2017529870 A5 JP2017529870 A5 JP 2017529870A5 JP 2017525496 A JP2017525496 A JP 2017525496A JP 2017525496 A JP2017525496 A JP 2017525496A JP 2017529870 A5 JP2017529870 A5 JP 2017529870A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- chain variable
- variable region
- ras
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 210000000805 cytoplasm Anatomy 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 235000001014 amino acid Nutrition 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000012202 endocytosis Effects 0.000 claims 1
- 210000001163 endosome Anatomy 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000012466 permeate Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 229940126586 small molecule drug Drugs 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140092687 | 2014-07-22 | ||
| KR10-2014-0092687 | 2014-07-22 | ||
| KR10-2015-0103214 | 2015-07-21 | ||
| KR1020150103214A KR101602876B1 (ko) | 2014-07-22 | 2015-07-21 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| PCT/KR2015/007627 WO2016013871A1 (ko) | 2014-07-22 | 2015-07-22 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529870A JP2017529870A (ja) | 2017-10-12 |
| JP2017529870A5 true JP2017529870A5 (enExample) | 2018-08-30 |
| JP6798988B2 JP6798988B2 (ja) | 2020-12-09 |
Family
ID=55354089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525496A Expired - Fee Related JP6798988B2 (ja) | 2014-07-22 | 2015-07-22 | 完全型免疫グロブリン形態の細胞質浸透能を有する抗体を利用して細胞内活性化されたｒａｓを抑制する方法及びその利用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10851177B2 (enExample) |
| EP (1) | EP3173099B1 (enExample) |
| JP (1) | JP6798988B2 (enExample) |
| KR (2) | KR101602876B1 (enExample) |
| CN (1) | CN106999575A (enExample) |
| AU (1) | AU2015292956B2 (enExample) |
| BR (1) | BR112017001306A2 (enExample) |
| CA (1) | CA2955265A1 (enExample) |
| IL (1) | IL250137B (enExample) |
| MX (1) | MX2017001012A (enExample) |
| RU (1) | RU2017103679A (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| CA3025757A1 (en) | 2016-05-27 | 2017-11-30 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
| EP3712180A4 (en) * | 2017-11-16 | 2021-08-11 | Orum Therapeutics Inc. | RAS INHIBITOR ANTIBODIES ACTIVATED IN A CELL BY INTERNALIZATION IN CYTOSOL OF THE CELL, AND ITS USE |
| US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
| JP2021532135A (ja) * | 2018-07-23 | 2021-11-25 | 中外製薬株式会社 | 標的細胞特異的な細胞質侵入抗原結合分子 |
| KR20200088780A (ko) * | 2019-01-15 | 2020-07-23 | 오름테라퓨틱 주식회사 | 세포질 침투성이 증진된 항체 |
| US20220177603A1 (en) * | 2019-05-01 | 2022-06-09 | Universidade De Santiago De Compostela | Intracellular delivery of anti-kras antibodies formulated into nanocapsules |
| TW202204420A (zh) * | 2020-04-30 | 2022-02-01 | 美商建南德克公司 | Ｋｒａｓ特異性抗體及其用途 |
| IL307396A (en) * | 2021-04-02 | 2023-12-01 | Massachusetts Gen Hospital | Methods for inhibiting RAS |
| CN117916258A (zh) | 2021-07-20 | 2024-04-19 | 亚洲大学校产学协力团 | 穿透进细胞以降解和去除靶蛋白的细胞穿透降解抗体及其用途 |
| US20250122308A1 (en) * | 2021-09-17 | 2025-04-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeting mutant kras with a mutation specific iga |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2706486B1 (fr) | 1993-06-16 | 1995-09-01 | Rhone Poulenc Rorer Sa | Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques. |
| CN1241574A (zh) | 1998-07-02 | 2000-01-19 | 中国人民解放军第四军医大学 | 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体 |
| AU2003219277A1 (en) * | 2002-03-14 | 2003-09-29 | Medical Research Council | Intracellular antibodies |
| GB0226727D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| WO2004046188A2 (en) | 2002-11-15 | 2004-06-03 | Medical Research Council | Anti-activated ras antibodies |
| KR20090008290A (ko) * | 2006-03-27 | 2009-01-21 | 글로브이뮨 | Ｒａｓ 돌연변이와 그에 관련된 조성물 및 방법 |
| MX2010007357A (es) | 2008-01-03 | 2011-03-03 | The Scripps Res Institute Star | Puesta de anti-cuerpos en objetivo mediante un dominio de reconocimiento modular. |
| KR100849941B1 (ko) * | 2008-04-29 | 2008-08-01 | 원우이에프엔지니어링주식회사 | 열 및 연기 화재감지장치 복합시험기 |
| US20110159569A1 (en) * | 2008-04-30 | 2011-06-30 | Ajou University IndustryAcademic Cooperation Found | Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same |
| KR101075123B1 (ko) * | 2008-10-24 | 2011-10-19 | 아주대학교산학협력단 | 핵산가수분해 능 및 암세포내 침투능력을 갖는 인간화된 항체 및 그 용도 |
| CN102209726A (zh) | 2008-11-11 | 2011-10-05 | 亚州大学校产学协力团 | 具有细胞穿透性、序列特异性和核酸水解性的抗体、其制备方法及包含所述抗体的药物组合物 |
| CN101402675B (zh) | 2008-11-28 | 2012-05-30 | 中国人民解放军第三军医大学第三附属医院 | 一种靶向抑制ανβ3阳性细胞增殖的环肽 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011140151A1 (en) | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| GB201103631D0 (en) * | 2011-03-03 | 2011-04-13 | Univ Leeds | Identification of candidate therapeutics |
| WO2012135831A1 (en) | 2011-04-01 | 2012-10-04 | Yale University | Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair |
| US9283272B2 (en) | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| WO2014042209A1 (ja) | 2012-09-14 | 2014-03-20 | 公益財団法人がん研究会 | ＥｐＣＡＭに結合するペプチド |
| US10011635B2 (en) | 2013-09-27 | 2018-07-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cyclic peptide conjugates and methods of use |
| WO2016013870A1 (ko) | 2014-07-22 | 2016-01-28 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| EP3277314A4 (en) | 2015-04-03 | 2018-08-29 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
| KR101790669B1 (ko) | 2015-10-14 | 2017-10-26 | 아주대학교산학협력단 | 개선된 분할 녹색 형광 단백질 상보 시스템 및 이의 용도 |
| CA3025757A1 (en) | 2016-05-27 | 2017-11-30 | Orum Therapeutics Inc. | Cytosol-penetrating antibody and use thereof |
| KR101836392B1 (ko) | 2016-08-17 | 2018-03-08 | 한림대학교 산학협력단 | 사이클릭 펩타이드를 포함하는 백신 조성물, 사이클릭 펩타이드에 대한 항체 또는 이를 포함하는 항암 조성물 |
| EP3712180A4 (en) | 2017-11-16 | 2021-08-11 | Orum Therapeutics Inc. | RAS INHIBITOR ANTIBODIES ACTIVATED IN A CELL BY INTERNALIZATION IN CYTOSOL OF THE CELL, AND ITS USE |
| US10787487B2 (en) | 2018-06-21 | 2020-09-29 | Orum Therapeutics Inc. | Cell/tissue-specific cell-penetrating antibodies |
-
2015
- 2015-07-21 KR KR1020150103214A patent/KR101602876B1/ko not_active Expired - Fee Related
- 2015-07-22 JP JP2017525496A patent/JP6798988B2/ja not_active Expired - Fee Related
- 2015-07-22 BR BR112017001306-1A patent/BR112017001306A2/pt not_active Application Discontinuation
- 2015-07-22 EP EP15825508.3A patent/EP3173099B1/en active Active
- 2015-07-22 MX MX2017001012A patent/MX2017001012A/es unknown
- 2015-07-22 RU RU2017103679A patent/RU2017103679A/ru not_active Application Discontinuation
- 2015-07-22 AU AU2015292956A patent/AU2015292956B2/en not_active Ceased
- 2015-07-22 CN CN201580045140.3A patent/CN106999575A/zh active Pending
- 2015-07-22 CA CA2955265A patent/CA2955265A1/en not_active Abandoned
- 2015-07-22 US US15/327,539 patent/US10851177B2/en not_active Expired - Fee Related
-
2016
- 2016-02-12 KR KR1020160016637A patent/KR101732553B1/ko not_active Expired - Fee Related
-
2017
- 2017-01-16 IL IL250137A patent/IL250137B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529870A5 (enExample) | ||
| JP2017529097A5 (enExample) | ||
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| RU2017103675A (ru) | Способ размещения в цитоплазме антител в виде полного иммуноглобулина путем проникновения антител через клеточную мембрану и его применение | |
| RU2017103679A (ru) | Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение | |
| JP2017029157A5 (enExample) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2020500510A5 (enExample) | ||
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2019503990A5 (enExample) | ||
| JP2011523550A5 (enExample) | ||
| JP2016185981A5 (enExample) | ||
| JP2016524463A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2015143226A5 (enExample) | ||
| JP2016519932A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| HRP20200036T1 (hr) | Postupci liječenja tauopatije | |
| JP2011509245A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2014506132A5 (enExample) | ||
| JP2018537421A5 (enExample) | ||
| JP2009535021A5 (enExample) |